| Literature DB >> 24455187 |
D N Baryakin1, D V Semenov1, A V Savelyeva2, O A Koval1, I V Rabinov1, E V Kuligina1, V A Richter1.
Abstract
11% of the human genome is composed of Alu-retrotransposons, whose transcription by RNA polymerase III (Pol III) leads to the accumulation of several hundreds to thousands of Alu-RNA copies in the cytoplasm. Expression of Alu-RNA Pol III is significantly increased at various levels of stress, and the increase in the Alu-RNA level is accompanied by a suppression of proliferation, a decrease in viability, and induction of apoptotic processes in human cells. However, the question about the biological functions of Pol III Alu-transcripts, as well as their mechanism of action, remains open. In this work, analogues of Alu-RNA and its evolutionary ancestor, 7SL RNA, were synthesized. Transfection of human breast adenocarcinoma MCF-7 cells with the Alu-RNA and 7SL RNA analogues is accompanied by a decrease in viability and by induction of proapoptotic changes in these cells. The analysis of the combined action of these analogues and actinomycin D or tamoxifen revealed that the decreased viability of MCF-7 cells transfected with Alu-RNA and 7SL RNA was due to the modulation of transcription. A whole transcriptome analysis of gene expression revealed that increased gene expression of the transcription regulator NUPR1 (p8), as well as the transcription factor DDIT3 (CHOP), occurs under the action of both the Alu- and 7SL RNA analogues on MCF-7 cells. It has been concluded that induction of proapoptotic changes in human cells under the influence of the Alu-RNA and 7SL RNA analogues is related to the transcriptional activation of the genes of cellular stress factors, including the endoplasmic reticulum stress response factors.Entities:
Keywords: 7SL RNA; Alu-RNA; Alu-repeats; MCF-7 human breast adenocarcinoma cells
Year: 2013 PMID: 24455187 PMCID: PMC3890993
Source DB: PubMed Journal: Acta Naturae ISSN: 2075-8251 Impact factor: 1.845
Fig. 1A schematic representation of the secondary structure of Alu-RNA (A) and 7SL RNA (B) according to [12]
The effect of Alu-RNA and 7SL RNA analogues on the viability, asymmetry, cell membrane permeability, and mitochondrial transmembrane potential of MCF-7 cells
| RN A* |
Decrease in | Proapoptotic changes in membrane*** |
Mitochondrial transmembrane | |||
|---|---|---|---|---|---|---|
| Ann V-/PI- | Ann V+/PI- | Ann V+/PI+ | without | with | ||
| Viable cells, % | Apoptotic | Secondary | ||||
| 7SL RN A | 19.0 ± 4.8 | 69.2 | 19.3 | 11.5 | 83.4 | 16.6 |
| Alu-RN A | 15.3 ± 6.5 | 68.7 | 13.8 | 17.5 | 85.6 | 14.4 |
| RN A MCF-7 | –2.8 ± 8.2 | 85.2 | 7.4 | 7.3 | 97.9 | 2.1 |
| Lipofectamine | 0 ± 2.5 | 89.9 | 6.8 | 3.3 | 99.7 | 0.3 |
* Cells were transfected with 1μg/ml RNA in a complex with Lipofectamine.
** Viability of cells incubated in the medium with Lipofectamine without RNA was taken as 100%.
*** Changes in the cell membrane were analyzed by flow cytofluorometry using annexin V (AnnV) conjugated to FITC and propidium iodide (PI).
**** Dissipation of the mitochondrial transmembrane potential was evaluated using flow cytofluorometry of cells stained with the mitochondrial dye JC-1 [23].
Effect of Alu-RNA and 7SL RNA analogues on MCF-7 cell viability in the presence of cytostatic agents
| Effector (IC40*) | Alu(+)-RN A | 7SL(+)-RN A | ||
|---|---|---|---|---|
| MTT -index ± SD, %** | p*** | MTT -index ± SD, %** | p*** | |
| Cisplatin (9.5 μM) | 25.7 ± 7.7 | 0.004 | 20.0 ± 3.5 | 0.001 |
| Cycloheximide (0.56 μM) | 17.9 ± 6.7 | 0.010 | 14.9 ± 7.5 | 0.026 |
| Interferon α (400 U/ml) | 17.8 ± 7.6 | 0.022 | 26.5 ± 7.9 | 0.009 |
| Methotrexate (33.3 μM) | 11.5 ± 10.2 | 0.171 | 26.5 ± 8.4 | 0.011 |
| Monensin (2.5 pM) | 3.8 ± 6.3 | 0.352 | 10.8 ± 5.1 | 0.021 |
| Tamoxifen (450 μM) | –1.2 ± 12.7 | 0.897 | –12.1 ± 12.6 | 0.244 |
| Actinomycin D (5.6 nM) | 21.5 ± 21.2 | 0.232 | -57.7 ± 22.6 | 0.031 |
* The empirically obtained effector concentrations are indicated at which cell viability decreased by 40% after incubation (with Lipofectamine) for 72 hrs.
** Additional decrease in the MTT-index in cells by the 72nd h after transfection with RNA. Viability of cells incubated in the medium with Lipofectamine, with an effector at the indicated concentration, and without RNA was taken as 0%.
*** p value for the Student’s t-test.
MCF-7 cell transcripts whose level varies under the action of the Alu-RNA analogue
| Transcript* | Identifier | Relative | Annotation |
|---|---|---|---|
| Increase in expression | |||
|
| NM_001042483 | 5.3 | Nuclear protein, transcriptional regulator |
| PER3 | NM_016831 | 5.1 | Period homolog 3 (Drosophila) |
|
| NM_006472 | 4.7 | Thioredoxin interacting protein |
|
| NM_133436 | 4.5 | Asparagine synthetase, transcript variant 1 |
| ZNF773 | NM_198542 | 4.3 | Zinc finger protein 773 |
| FAM119A | NM_001127395 | 4.1 | Family with sequence similarity 119, member |
| ZNF750 | NM_024702 | 4.1 | Zinc finger protein 750 |
|
| NM_145239 | 4.0 | Proline-rich transmembrane protein 2 |
| KCNE4 | NM_080671 | 3.9 | Potassium voltage-gated channel |
| C6ORF48 | NM_001040437 | 3.9 | Chromosome 6 open reading frame 48 |
| AUH | NM_001698 | 3.8 | AU RN A binding protein |
|
| NM_004083 | 3.8 | DNA-damage-inducible transcript 3 |
|
| NM_002281 | 3.7 | Keratin 81 |
|
| NM_194430 | 3.6 | Ribonuclease, RN ase A family 4 |
| FBXO15 | NM_152676 | 3.6 | F-box protein 15 |
| FLJ45244*** | NM_207443 | 3.6 | DICER1 antisense RN A 1 non-coding RN A |
| MTHFD2 | NM_001040409 | 3.5 | Methylenetetrahydrofolate dehydrogenase |
| Decrease in expression | |||
|
| NM_024955 | 0.15 | FAD-dependent oxidoreductase domain containing 2 |
| PPRC1 | NM_015062 | 0.19 | Peroxisome proliferator-activated receptor gamma, coactivator-related 1 |
|
| NM_007236 | 0.21 | Calcium binding protein P22 |
|
| NM_003311 | 0.21 | Pleckstrin homology-like domain, family A, member 2 |
| TMEM158 | NM_015444 | 0.21 | Transmembrane protein 158 |
| ATN1 | NM_001007026 | 0.22 | Atrophin 1 (ATN 1) |
|
| NM_206539 | 0.23 | Delta-like 2 homolog (Drosophila) |
| HPS1 | NM_182639 | 0.23 | Hermansky-Pudlak syndrome 1 |
| TMEM214 | NM_017727 | 0.23 | Transmembrane protein 214 |
| MED24 | NM_014815 | 0.24 | Mediator complex subunit 24 |
|
| NM_000445 | 0.24 | Plectin 1, intermediate filament binding protein 500 kDa |
| ZYX | NM_003461 | 0.24 | Zyxin |
| ACD | NM_022914 | 0.25 | Adrenocortical dysplasia homolog (mouse) |
| PCDH7 | NM_002589 | 0.25 | Protocadherin 7 (PCDH7) |
| RDH10 | NM_172037 | 0.25 | Retinol dehydrogenase 10 (all-trans) |
|
| NM_002083 | 0.26 | Glutathione peroxidase 2 (gastrointestinal) |
* Transcripts annotated in the RefSeq database (accessions NM, NR). The transcripts whose expression changed under the action of both Alu-RNA and 7SL RNA are shown in bold.
** Variation in the transcript amount in cells treated with Alu-RNA relative to the control cells treated with Lipofectamine.
*** The Illumina HT-12 probe sequence for the FLJ45244 gene coincides with the DICER-AS1 sequence (NR_015415).
MCF-7 cell transcripts whose level varies under the action of the 7SL RNA analogue
| Transcript* | Identifier | Relative | Annotation |
|---|---|---|---|
| Increase in expression | |||
|
| NM_001042483 | 4.5 | Nuclear protein, transcriptional regulator |
|
| NM_006472 | 4.3 | Thioredoxin interacting protein |
|
| NM_145239 | 4.3 | Proline-rich transmembrane protein 2 |
| PSPH | NM_004577 | 4.2 | Phosphoserine phosphatase |
|
| NM_133436 | 3.8 | Asparagine synthetase, transcript variant 1 |
| KY | NM_178554 | 3.8 | Kyphoscoliosis peptidase |
| FABP6 | NM_001445 | 3.7 | Fatty acid binding protein 6, ileal |
|
| NM_004083 | 3.6 | DNA-damage-inducible transcript 3 |
| CTSK | NM_000396 | 3.6 | Cathepsin K |
|
| NM_002281 | 3.6 | Keratin 81 |
| PFAAP5 | NM_014887 | 3.4 | Phosphonoformate immuno-associated protein 5 |
| NT5E | NM_002526 | 3.4 | 5'-Nucleotidase, ecto (CD73) |
| ARL3 | NM_004311 | 3.4 | ADP-ribosylation factor-like 3 |
|
| NM_025218 | 3.4 | UL16 binding protein 1 |
| BACE2 | NM_138992 | 3.4 | Beta-site APP-cleaving enzyme 2 |
|
| NM_194431 | 3.3 | Ribonuclease, RN ase A family 4 |
| Decrease in expression | |||
|
| NM_024955 | 0.16 | FAD-dependent oxidoreductase domain containing 2 |
|
| NM_002083 | 0.16 | Glutathione peroxidase 2 (gastrointestinal) |
|
| NM_001069 | 0.17 | Tubulin, beta 2A |
|
| NM_000445 | 0.19 | Plectin 1, intermediate filament binding protein |
| ZC3HAV1 | NM_024625 | 0.20 | Zinc finger CCC H-type, antiviral 1 |
| SLC35C1 | NM_018389 | 0.21 | Solute carrier family 35, member C1 |
|
| NM_001077261 | 0.21 | Nuclear receptor co-repressor 2 |
| PIGW | NM_178517 | 0.22 | Phosphatidylinositol glycan anchor biosynthesis, class W |
|
| NM_001044391 | 0.22 | Mucin 1, cell surface associated |
|
| NM_025136 | 0.23 | Optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) |
| PDPK1 | NM_002613 | 0.23 | 3-Phosphoinositide dependent protein kinase-1 |
| SLC29A3 | NM_018344 | 0.23 | Solute carrier family 29 (nucleoside transporters), member 3 |
| HCFC1 | NM_005334 | 0.24 | Host cell factor C1 (VP16-accessory protein) |
| FAHD1 | NM_001018104 | 0.24 | Fumarylacetoacetate hydrolase domain containing 1 (FAHD1) |
| PARP12 | NM_022750 | 0.24 | poly (ADP-ribose) polymerase family, member 12 |
| LRRC14 | NM_014665 | 0.25 | Leucine rich repeat containing 14 |
* Transcripts annotated in the RefSeq database (accessions NM, NR). The transcripts whose expression changed under the action of both Alu-RNA and 7SL RNA are shown in bold.
** Variation in the transcript amount in cells treated with Alu-RNA relative to the control cells treated with Lipofectamine.